期刊文献+

Ⅲ价轮状病毒基因重配疫苗免疫原性及对造血系统的影响

Immunogenicity and long-term hematological toxicity of Ⅲ valence rotavirus gene reassortment vaccine
原文传递
导出
摘要 目的:研究Ⅲ价轮状病毒基因重配疫苗对SD大鼠的免疫原性及对造血系统的长期毒性。方法:疫苗组大鼠(n=30)免疫3次,每次每只动物2 mL ig,第1次免疫后3周、第3次免疫后1和4周各处死大鼠10只,检测血清特异性抗体,血液学和骨髓。结果:在各时间点疫苗组血清抗体滴度均明显高于对照组。第1次免疫后3周时可测出针对G1,G2,G3,G4和G10型抗原的抗体,逐渐升高。针对G2,G3和G4型的抗体滴度明显高于G1和G10型(P<0.01或<0.05)。疫苗组大鼠LY计数和MCH出现了可逆性变化(P<0.05),但无明显毒性,大鼠骨髓象无明显改变。结论:Ⅲ价轮状病毒基因重配疫苗对大鼠有明显免疫原性,对造血系统无明显毒性。 Objective: To evaluate the immunogenicity and long-term hematological toxicity of Ⅲ valence rotavirus gene reassortment vaccine in Sprague-Dawley(SD) rats.Methods: Rats(n=30) were repeatedly ig immunized with Ⅲ valence rotavirus gene reassortment vaccine at 2 mL for 3 times.Three weeks after the first immunization,and 1 and 4 weeks after the third immunization,10 rats were respectively sacrificed for examination of the specific antibody against vaccine,hematology and bone marrow histopathology.Results: The antibody titers were significantly higher in vaccine group than control group at each detected point.The antibody against G1,G2,G3,G4 and G10 were found three weeks after the first immunization,and then increased gradually.The antibody titers of G2,G3 and G4 were significantly higher than G1 and G10(P0.01 or P0.05).The lymphocyte count and mean corpuscular hemoglobin(MCH) in vaccine group showed reversible changes,but did not show apparent toxicity.There were no apparent changes in bone marrow histopathology.Conclusion: Ⅲ valence rotavirus gene reassortment vaccine has immunogenicity against rats and has no apparent bone marrow toxicity in rats.
出处 《中国新药杂志》 CAS CSCD 北大核心 2010年第8期696-699,703,共5页 Chinese Journal of New Drugs
基金 国家科技支撑计划(2008BAI66B01) 甘肃省重大专项(0702NKDA042)
关键词 Ⅲ价轮状病毒基因重配疫苗 免疫原性 造血系统 长期毒性 Ⅲ valence rotavirus gene reassortment vaccine immunogenicity haematological system long-term toxicity
  • 相关文献

参考文献7

  • 1PARASHAR UD,HUMMELMAN EG,BRESEE JS,et al. Global illness and deaths caused by rotavirus disease in children [ J ]. Emerg Infect Dis ,2003,9 (5) :565 -572.
  • 2DENNEHY PH. Rotavirus vaccines:an overview[ J]. Clin Microbiol Rev,2008,21 ( 1 ) : 198 - 208.
  • 3GLASS RI, PARASHAR UD, BRESEE JS. Rotavirus vaccines: current prospects and future challenges [ J ]. Lancet, 2006,368 (9532) :323 -332.
  • 4DESSELBERGER U, ITURRIZA-GOMARA M, GRAY JJ. Rotavirus epidemiology and surveillance [ J ]. Novartis Found Symp, 2001,238 : 125 - 147 ; discussion 147 - 152.
  • 5WOOD D. On behalf of the WHO Informal Consultative Group. WHO informal consultation on quality,safety and efficacy specifications for live attenuated rotavirus vaccines Mexico City,Mexico, 8-9 February 2005[J]. Vaccine, 2005,23(48 -49):5478 - 5487.
  • 6WHO. Guidelines to assure the quality, safety and efficacy of live attenuated rotavirus vaccines (oral) [ S ]. Adopted by the 56th meeting of the WHO Expert Committee on Biological Standardization ,2005.
  • 7国家食品药品监督管理局药品审评中心.预防用生物制品临床前安全性评价技术审评一般原则[EB/OL].[2006-01-28].http://www.cde.org.cn/zdyz.do?method=largePage&id=55.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部